Article 81 — Union testing facilities (EU AI Act)

Article 81 of Regulation (EU) 2024/1689 — Union testing facilities. Official text, practical interpretation, key obligations and compliance implications.

Official Text Summary

Article 81 of Regulation (EU) 2024/1689 establishes the framework for the creation and designation of Union testing facilities — specialised bodies tasked with providing independent, high-quality technical testing, inspection, and examination services in support of the EU AI Act's enforcement architecture.

Under Article 81, the European Commission is empowered to designate existing testing facilities as Union testing facilities where a specific testing need has been identified at Union level, particularly where national infrastructure is insufficient or unevenly distributed across Member States. These facilities are intended to complement the existing conformity assessment ecosystem by making advanced technical capability available across the single market.

The article provides that Union testing facilities shall operate in a manner that ensures impartiality, technical competence, and independence from commercial interests. Designated facilities must meet specific technical and organisational requirements laid down by the Commission, including requirements concerning confidentiality, liability, and access conditions.

Article 81 also addresses access by small and medium-sized enterprises (SMEs) and start-ups, reflecting the legislator's intent to lower barriers to compliant market entry. The Commission retains oversight of the network of Union testing facilities and may coordinate their activities to ensure coherent and consistent testing standards across Member States, avoiding duplication and fostering trust in the results produced.

What This Means in Practice

For most AI system providers, Article 81 operates in the background of the compliance process — but it carries direct practical significance for specific actors and scenarios.

Market surveillance authorities benefit most immediately. Where a national authority lacks the technical infrastructure to test a sophisticated AI system — for example, a high-risk AI system used in biometric identification or critical infrastructure management — they can refer the system to a Union testing facility for independent technical analysis. This is particularly relevant for cross-border enforcement scenarios involving AI systems deployed in multiple Member States.

Notified bodies may also draw on Union testing facilities for complex or novel technical questions that fall outside their in-house expertise, supporting more robust conformity assessments for high-risk AI systems under Annex III.

Providers of high-risk AI systems, especially SMEs and start-ups, gain a practical avenue to access state-of-the-art testing environments that would otherwise be financially or logistically inaccessible. This can be particularly valuable during pre-market validation, supporting voluntary pre-certification testing before a formal conformity assessment is initiated.

Concrete example: A mid-sized company developing an AI-based medical diagnostic tool may lack the resources to commission full-scale adversarial robustness testing. Under Article 81, it could request access to a Commission-designated Union testing facility equipped with the relevant datasets and computational resources, obtaining a credible technical report that strengthens its technical documentation under Article 11 and supports its conformity assessment under Article 43.

The practical utility of Union testing facilities will grow over time as the Commission progressively designates facilities and as market surveillance activity intensifies post-2026.

Key Obligations

• Commission designation power: The European Commission is responsible for identifying testing needs at Union level and formally designating facilities as Union testing facilities, establishing the criteria, procedures, and conditions that govern their operation.
• Technical and organisational requirements: Designated Union testing facilities must satisfy specific requirements for impartiality, independence, technical competence, confidentiality, and governance, ensuring the reliability and credibility of their outputs.
• Support to market surveillance authorities: Union testing facilities are mandated to make their services available to national market surveillance authorities carrying out enforcement activities under Chapter VII of the Regulation, including product testing and post-market investigations.
• Access for SMEs and start-ups: The framework explicitly preserves access for smaller operators, recognising that equitable access to high-quality testing infrastructure is a precondition for fair competition and broad compliance across the single market.
• Coordination across Member States: The Commission may coordinate the network of Union testing facilities to prevent duplication, ensure consistent methodologies, and maintain uniform technical standards across national jurisdictions.
• Operational independence: Union testing facilities must operate free from undue influence by any party whose AI systems they test, maintaining structural and financial independence in line with the requirements applicable to notified bodies and accredited laboratories.

Relationship to Other Articles

Article 81 is embedded within the post-market monitoring and market surveillance framework of Title IX and must be read alongside several interconnected provisions.

It directly supports Article 74 (market surveillance and control of AI systems in the Union market) by providing the technical infrastructure that surveillance authorities need to discharge their investigative obligations effectively. It also complements Article 43 (conformity assessment) and Article 44 (certificates of conformity), as Union testing facilities may contribute technical input that informs conformity assessment decisions by notified bodies designated under Article 41.

The technical documentation requirements of Article 11 and the quality management obligations of Article 17 are relevant because testing facility outputs may be incorporated into a provider's technical file. Article 33 (high-risk AI systems: conformity assessment procedures) and Annex III (list of high-risk AI systems) define the scope of systems most likely to be referred to Union testing facilities.

For SME-related provisions, Article 81 aligns with Article 62 (support measures for operators that are SMEs, including start-ups), reinforcing the Regulation's broader objective of ensuring that the compliance burden does not structurally disadvantage smaller market participants.

Compliance Timeline

Article 81 falls within the general provisions of the EU AI Act that became applicable 24 months after entry into force — that is, from 1 August 2026 — the same date as the main obligations for high-risk AI systems under Annex III (excluding those covered by the earlier December 2026 deadline for systems already regulated under Union harmonisation legislation listed in Annex I).

Key reference dates for the broader compliance context:

• 1 August 2024 — Regulation (EU) 2024/1689 entered into force.
• 2 February 2025 — Prohibitions on unacceptable-risk AI practices (Title II) became applicable.
• 2 August 2025 — GPAI model obligations (Title VIII) and governance provisions (Title VII, including the AI Office) became applicable.
• 2 August 2026 — Article 81 and the full market surveillance framework became applicable; Union testing facility designations expected to begin.
• 2 December 2026 — High-risk AI systems under Annex I (safety-component products) subject to full obligations.
• 2 August 2027 — High-risk AI systems listed in Annex III that are also covered by existing Union harmonisation legislation fully subject to all obligations.

Organisations operating in sectors where Union testing facilities are expected to be active — medical devices, biometrics, critical infrastructure, employment, education — should monitor Commission implementing acts and designations as they emerge throughout 2026 and 2027.